AN2 Therapeutics (ANTX) Current Leases (2022 - 2023)
AN2 Therapeutics' (ANTX) quarterly Current Leases came in at $13000.0 in Q2 2023, little changed year-on-year from $13000.0 in Q2 2022, and down 61.76% on a QoQ basis from $34000.0 in Q1 2023.
AN2 Therapeutics (ANTX) Current Leases (2022 - 2023) Analysis & Trends
AN2 Therapeutics (ANTX) has 2 years of Current Leases data on file, last reported at $13000.0 in Q2 2023.
- On a quarterly basis, Current Leases changed 0.0% year-over-year to $13000.0 in Q2 2023; TTM through Jun 2023 was $13000.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $53000.0, changed N/A from the prior year.
- Current Leases for Q2 2023 stood at $13000.0, down from $34000.0 in the prior quarter.
- Over the last five years, Current Leases for ANTX reached as high as $73000.0 in Q3 2022 and fell as low as $13000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 73,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 32,000.00 |